Ongericimab Injection Reducing Recurrence of Ischemic Stroke
A phase 3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 4810 participants.
Also called NCT07242599
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; single masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 4,810 participants
- Sponsor
- Registry
-
NCT07242599
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- China
- Registry status
- Not yet recruiting
Technical summary
Registry record NCT07242599. Randomized; single masking; primary purpose treatment. Start 2026-04-22 (anticipated); primary completion 2029-04-01 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Ongericimab Injection Reducing Recurrence of Ischemic Stroke
- Acronym
- ORIS
- Condition
- Ischemic Cerebral Infarction
- Intervention (Combination product)
- High target group
- Intervention (Combination product)
- Low target group
- Lead sponsor
- Beijing Tiantan Hospital
Record details
- Record id
cardio:ct-nct07242599- Content hash
1efc35a1887b8a4033521b43fc74fc536bfc4252540a83d9542c6421c2201904